Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Cleveland Clinic Launches Center for Young-Onset Colorectal Cancer

September 30th 2021

Cleveland Clinic has established a center focused on the diagnosis, care, and research of young-onset colorectal cancer.

Later-Line Therapy in Metastatic CRC Calls for Safety Considerations in Refined Decision Making

September 30th 2021

Kanwal P.S. Raghav, MBBS, MD, discussed nuances to treatment selection in mCRC, the significance of the phase 2 ReDOS trial with regorafenib, and how the paradigms for mCRC, HCC, and gastroesophageal cancers have expanded from areas of unmet need to ones with more robust armamentariums.

Dr. Weiss on the Efficacy Results of the KRYSTAL-1 Trial in KRAS G12C–Mutated CRC

September 29th 2021

Jared Weiss, MD, discusses the efficacy results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C–mutated colorectal cancer.

FDA Approves Cetuximab Plus Encorafenib for BRAF V600E–Mutant Metastatic CRC After Prior Therapy

September 29th 2021

The FDA has granted approval of a new indication for cetuximab plus encorafenib for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by a FDA-approved test, after prior therapy.

Dr. Cohen on the Shortcomings of Trials Evaluating Cytoreductive Surgery and HIPEC in CRC

September 24th 2021

Stacey A. Cohen, MD, discusses the shortcomings of clinical trials evaluating cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.

Dr. Hubbard on the Barriers of Widely Implementing ctDNA ​Testing in CRC

September 22nd 2021

Joleen M. Hubbard, MD, discusses the barriers of implementing circulating tumor DNA into widespread clinical practice in colorectal cancer.

High HER2 Expression Is Linked With Improved Outcomes With Trastuzumab Deruxtecan in HER2+ mCRC

September 21st 2021

Fam-trastuzumab deruxtecan-nxki led to improved responses in patients with higher HER2 expression at baseline, whereas responses were seen irrespective of RAS- and PIK3CA mutation status and blood tumor mutational burden levels in patients with HER2-positive, metastatic colorectal cancer.

Dr. Mogal on the Role of Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis

September 21st 2021

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the role of cytoreductive surgery in colorectal peritoneal carcinomatosis.

Adavosertib Improves PFS in RAS-/TP53-Mutant Metastatic Colorectal Cancer

September 21st 2021

Adavosertib demonstrated a 65% reduction in the risk of disease progression or death compared with active monitoring in patients with TP53-/RAS-mutant metastatic colorectal cancer following first-line chemotherapy.

Dr. Raghav on Regorafenib Dose Optimization in CRC

September 21st 2021

Kanwal Raghav, MBBS, MD, discusses optimal dosing strategies for regorafenib in patients with colorectal cancer.

Dr. Wainberg on the Need for Continued Enrollment to Clinical Trials in CRC

September 20th 2021

Zev A. Wainberg, MD, discusses the importance of enrolling patients with colorectal cancer to clinical trials, despite the difficulties caused by COVID-19.

Adagrasib Shows Impressive Activity in KRAS G12C–Mutant CRC

September 19th 2021

Adagrasib alone or in combination with cetuximab elicited encouraging antitumor activity and safety in heavily pretreated patients with KRAS G12C–mutant colorectal cancer, according to findings from the phase 1/2 KRYSTAL-1 trial.

Dr. Marshall on Considerations for Third-Line Therapeutic Options in CRC

September 14th 2021

John L. Marshall, MD, discusses factors to consider in the third-line treatment setting for patients with colorectal cancer.

Dr. Mogal on Patient Selection for Cytoreductive Surgery in CRC

September 13th 2021

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the importance of patient selection for cytoreductive surgery in colorectal cancer with peritoneal involvement.

Dr. Cohen on the Importance of Patient Selection for HIPEC Surgery in CRC

September 9th 2021

Stacey A. Cohen, MD, discusses the importance of patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.

Dr. Raghav on First-Line Treatment Options in CRC

September 7th 2021

Kanwal Raghav, MBBS, MD, discusses first-line treatment options for patients with colorectal cancer.

Dr. Mogal on the Incidence and Prognosis of Peritoneal Carcinomatosis in CRC

September 3rd 2021

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the incidence and prognosis of peritoneal carcinomatosis in colorectal cancer.

Dr. Cohen on Tailoring Treatment to Individual Subtypes in CRC

September 2nd 2021

Stacey A. Cohen, MD, discusses tailoring treatment approaches to individual subtypes in colorectal cancer.

Pembrolizumab Approved in Japan for Select Breast Cancer and Colorectal Cancer

August 26th 2021

The Japan Pharmaceuticals and Medical Devices Agency has approved the use of pembrolizumab in the treatment of patients with PD-L1–positive, hormone receptor–negative and HER2-negative, inoperable or recurrent breast cancer, and for single-agent use in patients with unresectable, advanced, or recurrent microsatellite instability–high colorectal cancer.

Increased Vitamin D Intake Associated With Lower Risk of Early-Onset CRC

August 25th 2021

Increased intake of vitamin D was associated with a decreased risk of early-onset colorectal cancer and precursors in younger women between the ages of 25 years and 42 years.

NEXT PAGE
PREVIOUS PAGE